NKMAX said on Thursday that it has received FDA approval for its natural killer (NK) cell therapy SNK01 to treat Parkinson's disease under the Expanded Access Program (EAP). NKMAX has received sympathetic approval from the FDA for its NK cell therapy, SNK01, to treat Parkinson's disease ...
NK CellTech Co., Ltd. (NK CellTech) is a leading biotech company dedicated to the discovery and development of innovative technology of NK cell therapy. The R&D team has over 30 years of experiences in the research and clinical practice of NK cells, which dedicates NK Cell...
据美国食品药品监督管理局(FDA)官网消息,2024年11月8日,一款新型CAR-T疗法,即obecabtageneautoleucel(obe-cel;Aucatzyl)获FDA批准,用于复发或难治性B细胞前体急性淋巴细胞白血病(ALL)成年患者的治疗。 据悉,Aucatzyl是FDA批准的首...
Data has shown the investigational cell therapy is well-tolerated in patients and showed preliminary impacts on cognition. The FDA granted fast track designation to troculeucel, an investigational, ex vivo expanded autologous natural killer (NK) cell therapy, for the treatment of moderate...
[5]https://www.amgen.com/newsroom/press-releases/2024/05/fda-approves-imdelltra-tarlatamabdlle-the-first-and-only-tcell-engager-therapy-for-the-treatment-of-extensivestage-small-cell-lung-cancer [6]https://www.fda.g...
通过与APC表面的主要组织相容性复合体II(MHC II)相结合,能够激活APCs,这会激活和增殖CD8阳性细胞毒性T细胞、CD4阳性辅助性T细胞、树突状细胞、NK细胞和单核细胞,提升患者对癌症抗原的免疫反应。此外,Efti还能上调IFN-γ和CXCL10等关键生物分子的表达,进一步增强免疫系统对抗癌症的能力。Keytruda通过阻断具有免疫抑制功能...
in the press release. "With Omvoh approved in both Crohn's disease and ulcerative colitis, more patients now have a treatment option that may provide long-term disease control and address key symptoms that matter most to them, reflecting Lilly's ongoing commitment to elevate care and improve ...
HAIRY cell leukemiaThe FDA approved the interleukin (IL)15 superagonist, N-803, for the treatment of bladder cancer in April 2024, marking the first cytokine in over 30 years to receive FDA approval for cancer treatment. IL-15, discovered in 1994, is a powerful lymphocyte growth factor for ...
Many cancers exploit PD-1 to evade immune attacks, prompting anti-PD-1 therapies to block this pathway and reactivate immune cells. However, prolonged CD8(+) T-cell stimulation by these therapies can drive the cells into a terminally exhausted state, diminishing their ability t...
After decades of work, in February 2024, TIL (lifileucel) in combination with IL-2 received FDA approval for the treatment of melanoma [8], which is the first approved adoptive cell therapy using lymphocytes for the treatment of a solid tumor. Fig. 1 Timeline of key events related to ...